Published: August 02, 2011
Cannabis Science To Launch A Worldwide Online Cannabis Patient Tracking System For Patients, Doctors, and Company Interactions Over The Internet
COLORADO SPRINGS, Colo. - (BUSINESS WIRE) - Cannabis Science Inc. (NASD OTCBB: CBIS) a pioneering US biotech company
developing pharmaceutical cannabis products, is pleased announce its
plans to launch an online cannabis patient tracking system, which will
be made available worldwide for private and secure usage and results
tracking. This new initiative is based on the large amount of new
inquiries from patients, relatives, and friends from all over the world;
all inquiring about treatments for various critical ailments the Company
has been focused on for Cannabis Science's proprietary medical cannabis
delivery methods and formulations.
The Company is in the process of creating a new section on its website
to allow all Company approved users can track their usage and provide
valuable patient input, and medical documentation regarding their
experiences with medical marijuana and cannabis extracts. This data will
go hand in hand with our licensed product development partners and their
patients who wish to use it all adding to the cumulative international
research and present critical patient data so that other patients may
make informed decisions regarding their health care treatment options
while furthering our studies and product development.
Dr. Robert Melamede, Ph. D., Cannabis Science Inc., President & CEO
said, "We feel it is essential that CBIS work with patients around the
world to foster policy changes that will increase the demand and
availability of our products, in line with our expanding business
opportunities that are developing through new partnerships and license
agreements to maximize market potential for the Company and
shareholders."
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade
medical marijuana research and development. The Company works with world
authorities on phytocannabinoid science targeting critical illnesses,
and adheres to scientific methodologies to develop, produce and
commercialize phytocannabinoid-based pharmaceutical products. In sum, we
are dedicated to the creation of cannabis-based medicines, both with and
without psychoactive properties, to treat disease and the symptoms of
disease, as well as for general health maintenance.
This Press Release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Act of 1934. A statement containing works such as
"anticipate," "seek," intend," "believe," "plan," "estimate," "expect,"
"project," "plan," or similar phrases may be deemed "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Some or all of the events or results anticipated by
these forward-looking statements may not occur. Factors that could cause
or contribute to such differences include the future U.S. and global
economies, the impact of competition, and the Company's reliance on
existing regulations regarding the use and development of cannabis-based
drugs. Cannabis Science, Inc. does not undertake any duty nor does it
intend to update the results of these forward-looking statements.

Cannabis Science Inc.
Dr. Robert J. Melamede
President
& CEO
info@cannabisscience.com
www.cannabisscience.com
1-888-889-0888
Copyright © 2012, Business Wire, Inc., All rights reserved.
Copyright © 2012, NewsBlaze,
Daily News